HOME >> MEDICINE >> NEWS
Cholesterol Carriers Better Predictors Than Cholesterol For Second Heart Attack

DALLAS, May 18 -- Two proteins that carry cholesterol in the blood may provide a better way to measure heart attack risk than the usual cholesterol blood test, report researchers in today's Circulation: Journal of the American Heart Association.

"Because the two proteins are more sensitive heart disease risk detectors than cholesterol, they may identify more individuals at risk and one day replace cholesterol testing," says the study's lead author, Arthur J. Moss, M.D., professor of medicine (cardiology) at the University of Rochester Medical Center, Rochester, N.Y.

The association between the proteins -- apolipoprotein (apo) A-1 and apolipoprotein (apo) B -- and heart attack risk held true even in the presence of heart disease risk factors including, smoking, diabetes, high blood pressure and high blood levels of cholesterol.

(Apo) A-1 and apo B carry cholesterol in the bloodstream. Apo B is a cholesterol donor, while apo A-1 is a cholesterol scavenger.

Researchers also identified a third protein, D-dimer, which was associated with heart attack risk. D-dimer is a breakdown product in the blood when clots form. Elevated levels of D-dimer indicate excess clotting or coagulation activity in the blood.

Individuals with the blood protein profile of low apo A-1, high apo B, and high D-dimer levels were eight times more likely than others in the study to experience a second heart attack within two years, Moss says. Patients with an abnormal blood level of only one of these proteins were twice as likely to experience another heart attack within two years.

When apo B levels are high, apo B deposits cholesterol on the inside surface of the plaque. Then it moves into the plaque, thereby increasing the size of the fatty deposit. Ordinarily, apo A-1 would pick up these cholesterol deposits before they enter the plaque. However, if apo A-1 levels are low, the process does not go as expected. Instead, the cholesterol accumulates and for
'"/>

Contact: Carole Bullock
caroleb@heart.org
214-706-1279
American Heart Association
18-May-1999


Page: 1 2 3

Related medicine news :

1. Cholesterol under-treated in high-risk women in managed care study
2. Cholesterol-lowering drug may also reduce risk of blood clots
3. Cholesterol-lowering drug may slow Alzheimers progression
4. Cholesterol-lowering medications may reduce risk of glaucoma
5. Cholesterol levels fluctuate with the seasons
6. Cholesterol-lowering drugs may help stroke patients get well
7. Cholesterol drugs may lower risk for mental impairment after stroke
8. Cholesterol drug increases pain-free walking distance
9. Cholesterol drug helps heart failure patients without high cholesterol
10. Cholesterol drug could lead to new therapy for multiple sclerosis
11. Cholesterol fighting drugs may also have protective effects against multiple sclerosis

Post Your Comments:
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay ... (IVF) -- the incubation of embryos in a laboratory dish ... vagina, new research suggests. Scientists from the United States ... sharply cut costs for pricey IVF procedures among certain women. ... who don,t live near big-city assisted reproduction centers, the researchers ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... officials on Monday officially tightened guidelines for health workers treating ... exposure and use of a respirator at all times. ... issue the tougher rules after two Dallas nurses contracted Ebola ... United States, Liberian national Thomas Eric Duncan. Nina Pham is ...
(Date:10/20/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... is the must-have source of thousands of facts, figures ... 72 countries and 68 medical sector forecast categories the ... you with global, regional and national views on the ... future outlook. , The report gives you data for ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus ... a biopharmaceutical company leading the discovery and ... announced that it has demonstrated human proof-of-concept ... clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated ... of hepatitis C virus infection ("HCV").  Interim ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8
Cached News: